Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Details)

v3.7.0.1
Fair Value Measurements (Details) - USD ($)
6 Months Ended
Jun. 30, 2017
Dec. 31, 2016
Aug. 31, 2014
2019 convertible senior notes      
Liabilities:      
Principal amount outstanding $ 245,000,000 $ 245,000,000  
2019 convertible senior notes | Senior Notes      
Liabilities:      
Principal amount outstanding     $ 245,000,000.0
Estimated fair value of debt 405,500,000    
Recurring      
Assets:      
Assets, fair value 116,219,000 126,187,000  
Liabilities:      
Liabilities, fair value 4,297,000 3,388,000  
Recurring | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 86,000 101,000  
Recurring | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 1,503,000 1,503,000  
Recurring | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 2,357,000 1,413,000  
Recurring | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 351,000 371,000  
Recurring | Short-term Investments [Member]      
Assets:      
Assets, fair value 112,404,000 122,296,000  
Recurring | Note receivable Viking Therapeutics, Inc.      
Assets:      
Assets, fair value $ 3,207,000 3,207,000  
Liabilities:      
Volatility of common stock 75.00%    
Recurring | Investment in warrants      
Assets:      
Assets, fair value $ 608,000 684,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Assets:      
Assets, fair value 2,946,000 3,738,000  
Liabilities:      
Liabilities, fair value 351,000 371,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 351,000 371,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments [Member]      
Assets:      
Assets, fair value 2,338,000 3,054,000  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Note receivable Viking Therapeutics, Inc.      
Assets:      
Assets, fair value 0 0  
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment in warrants      
Assets:      
Assets, fair value 608,000 684,000  
Recurring | Significant Other Observable Inputs (Level 2)      
Assets:      
Assets, fair value 110,066,000 119,242,000  
Liabilities:      
Liabilities, fair value 2,357,000 1,413,000  
Recurring | Significant Other Observable Inputs (Level 2) | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2) | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 2,357,000 1,413,000  
Recurring | Significant Other Observable Inputs (Level 2) | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2) | Short-term Investments [Member]      
Assets:      
Assets, fair value 110,066,000 119,242,000  
Recurring | Significant Other Observable Inputs (Level 2) | Note receivable Viking Therapeutics, Inc.      
Assets:      
Assets, fair value 0 0  
Recurring | Significant Other Observable Inputs (Level 2) | Investment in warrants      
Assets:      
Assets, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3)      
Assets:      
Assets, fair value 3,207,000 3,207,000  
Liabilities:      
Liabilities, fair value 1,589,000 1,604,000  
Recurring | Significant Unobservable Inputs (Level 3) | Current contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 86,000 101,000  
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-CyDex      
Liabilities:      
Liabilities, fair value 1,503,000 1,503,000  
Recurring | Significant Unobservable Inputs (Level 3) | Long-term contingent liabilities-Metabasis      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3) | Liability for amounts owed to former licensees      
Liabilities:      
Liabilities, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3) | Short-term Investments [Member]      
Assets:      
Assets, fair value 0 0  
Recurring | Significant Unobservable Inputs (Level 3) | Note receivable Viking Therapeutics, Inc.      
Assets:      
Assets, fair value 3,207,000 3,207,000  
Recurring | Significant Unobservable Inputs (Level 3) | Investment in warrants      
Assets:      
Assets, fair value $ 0 $ 0